Drug Target Review

AUGUST 9, 2024

She has over a decade of experience in clinical and scientific research with more than 20 high impact research publications to her name, focusing on combined therapies for optimal disease control and increased quality of life. References Allen, L. Popovich, N. G., & Ansel, H. Lippincott Williams & Wilkins.

Science 59

Science Drugs Compliance Drug Development 59

The Pharma Data

NOVEMBER 15, 2020

In addition, Dr. Lee Babiss, a committed director since 2010, has announced his retirement and has stepped down from the board. This prestigious group of professionals will help lead the Company as it prepares for potential commercialization of its investigational cell therapy, MultiStem ®. About Athersys.

Clinical Trials 40

Clinical Trials Trials Production Therapies 40

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. About IGM Biosciences, Inc.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

MAY 15, 2023

The preliminary data were disclosed at the 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Lisbon, Portugal. Five Neisseria meningitidis serogroups (A, B, C, W, and Y) account for nearly all invasive meningococcal disease (IMD) cases in most of the world.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

The Pharma Data

MARCH 29, 2022

Global Head of Research and Development, Sanofi “We look forward to this collaboration with IGM Biosciences, a pioneer in a new class of antibody medicines for the treatment of cancer, immunology , and inflammatory diseases. Sanofi has also expressed an interest in purchasing up to $100M of IGM non-voting common stock in a public financing.

Clinical Trials 52

Clinical Trials Engineering Licensing Licensing 52

Codon

FEBRUARY 27, 2024

Most square centimeters of our built environments transmit next to no disease (think of walls, which we rarely so much as brush in passing), but some are touched with extraordinary frequency. Diarrheal diseases—attributed to viruses, such as noroviruses, which are spread via fomite transmission—killed about 1.5

Virus 70

Virus Hospitals Production Regulations 70

The Pharma Data

OCTOBER 14, 2020

It was granted orphan drug designation for the treatment of narcolepsy in 2010. WAKIX is not recommended in patients with end-stage renal disease (ESRD). WAKIX is not recommended in patients with end-stage renal disease. since Q4 2019. WAKIX is a selective histamine 3 (H?) receptor antagonist/inverse agonist. Adverse Reactions.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

The Pharma Data

AUGUST 3, 2021

end-stage renal disease (ESRD) bundled payment system, dialysis clinics rapidly implemented new treatment protocols, switching patients from Parsabiv to generic oral cinacalcet. In July, the FDA accepted the Biologics License Application and granted Priority Review for tezepelumab for the treatment of asthma. Tezepelumab. Tax Petition.

Biosimilars 52

Biosimilars Production Treatment FDA 52

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red. The lighter stems are from wildtype poplar trees. From Sulis D.B. in Science. From McKyton et al. in Current Biology.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. They’re talking about a patient who has a rare genetic disease. ” Gene-edited poplar tree stems appear red. The lighter stems are from wildtype poplar trees. From Sulis D.B. in Science. From McKyton et al. in Current Biology.

Therapies 52

Therapies RNA DNA Engineering 52

LifeSciVC

OCTOBER 28, 2024

In-licensing molecules from other players, due to a partner’s strategic shifts, budget challenges, or geographic access, can be a great way to jumpstart early stage companies around more advanced assets. Management talent was spread thinly and disease areas and modalities became hyper-competitive quickly.

Licensing 96

Licensing Licensing Marketing Targeted Protein Degradation 96

Agency IQ

JUNE 16, 2023

See Asbestos Disease Awareness Organization v. Final Rule Stage Clean Water Act Section 401: Water Quality Certification 2040-AG12 August 2023 Clean Water Act (CWA) section 401 provides States and Tribes with a powerful tool to protect the quality of their waters from adverse impacts resulting from federally licensed or permitted projects.

Regulations 40

Regulations Compliance Production Science 40

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. How are disease targets selected for challenge trials?

Vaccine 126

Vaccine Trials Disease Treatment 126

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. European Centre for Disease Prevention and Control. 2010 Jun 23;28(29):4558-65.

FDA 52

FDA Vaccine Virus Clinical Trials 52

Codon

AUGUST 10, 2023

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Progress in biology is arguably moving faster today than at any point in the course of human history. Nature Reviews Genetics (2010). Link The second decade of synthetic biology: 2010–2020 , by Meng F. & Drug Discovery Today: Disease Models (2008).

DNA 98

DNA Cell Biology Molecular Biology Engineering 98

Agency IQ

JULY 12, 2024

Proposed Rule Pediatric Study Plan Requirements for New Drug and Biologics License Applications October 2024 FDA is proposing to amend its existing regulations and add new regulations pertaining to submission of required initial pediatric study plans (iPSPs) under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Regulations 40

Regulations FDA Science Production 40

Codon

AUGUST 10, 2023

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Last edit: 13 September 2023 Progress in biology is arguably moving faster today than at any point in the course of human history. Nature Reviews Genetics (2010). Link The second decade of synthetic biology: 2010–2020 , by Meng F. & Science (2010).

DNA 52

DNA Cell Biology Engineering Molecular Biology 52

Codon

FEBRUARY 23, 2025

Countries supported by PEPFAR saw HIV cases drop by 52 percent in 2023 compared to 2010, outpacing the 39 percent global decline. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates. For that reason, long-term preventatives are probably a better strategy for controlling the disease.

Clinical Trials 71

Clinical Trials Virus Vaccine DNA 71